TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06123338: A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Sponsor: Memorial Sloan Kettering Cancer Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 49 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$2,032,800

Rescue Site Savings

+$1,339,800

Unlock Full NCT06123338 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06123338 Rescue Dossier →